chiudiNovità
NEW! SEMEN QUALITY ANALYZER!!
GRAZIE ALLA PARTNERSHIP CON 
TEMA RICERCA PUO’ OFFRIRE IL SEMEN QUALITY ANALYZER CON UN CONTRATTO DI LOCAZIONE
OPERATIVA!
TDM and Drug Of Abuse assays:
One Resource MULTIPLE TECHNOLOGIES
ARK™ Technology
ARK assays employ a homogeneous enzyme immunoassay technology based on competition between drug in the specimen and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for binding to antibody reagent. As the latter binds antibody, enzyme activity decreases. In the presence of drug from the specimen, enzyme activity increases and is directly proportional to the drug concentration. Active enzyme converts the coenzyme nicotinamide adenine dinucleotide (NAD) to NADH that is measured spectrophotometrically as a rate of change in absorbance. Endogenous serum G6PDH does not interfere with the results because the coenzyme NAD functions only with the bacterial enzyme used in the assay.
QMS™ (Quantitative Microsphere System)
Is based on the competitive inhibition immunoassay principle: if the drug targeted by the assay is present in the sample, these free drug molecule compete with a microparticle-bound drug in one reagent for a limited number of antibody combining sites supplied by antibody in a second reagent. The competition for antibody binding sites inhibits the ability of the antibody to agglutinate the drug-coated microparticles.
CEDIA™ (Cloned Enzyme Donor ImmunoAssay)
Is a method in single fase, competitive binding process that combines analyte-specific antibodies and two genetically engineered fragments of bacterial enzyme B- galactosidase to accutately end reliably detect the presence of drugs and their metabolites as other substance in serum, plasma, whole blood, urine and oral fluid.
